Alaunos Therapeutics (TCRT) announced the appointment of Robert Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. Prior to joining his current company, Dr. Hofmeister spent almost seven years in scientific leadership at TCR2 Therapeutics (TCRR), a company developing novel therapies leveraging the TCR complex to fight both solid tumors and hematologic malignancies, culminating in the role of Chief Scientific Officer
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TCRT:
- Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
- Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
- Alaunos Therapeutics assumed with an Overweight at Wells Fargo
- Alaunos Therapeutics reports Q4 EPS (4c), consensus (7c)
- Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results